PDS Biotechnology Corp Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
PDS Biotechnology Corp (PDSB) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $887.09 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-13
- PDS Biotechnology Corp increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $370.50K.
- PDS Biotechnology Corp increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was $516.59K.
- PDS Biotechnology Corp increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was -$1.34M.
- PDS Biotechnology Corp increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $622.31K, a 75.43% decline year-over-year.
- PDS Biotechnology Corp increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was -$2.10M, a 603.93% decline from fiscal 2024.
- PDS Biotechnology Corp increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $416.52K.
- PDS Biotechnology Corp increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was -$5.89M, a 196.13% decline from fiscal 2022.
- PDS Biotechnology Corp increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $6.13M, a 1254.17% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $370.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $887.09K 10-Q · filed 2026-08-13 | -$452.92K derived: sum of 3 quarters · filed 2026-08-13 | $169.38K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $516.59K 10-Q · filed 2026-05-14 | -$823.42K derived: sum of 2 quarters · filed 2026-05-14 | -$201.11K derived: sum of 3 quarters · filed 2026-05-14 | -$1.52M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$717.70K derived: sum of 2 quarters · filed 2026-03-30 | -$2.03M derived: sum of 3 quarters · filed 2026-08-13 | -$2.10M 10-K · filed 2026-03-30 |
| 2025-09-30 | $622.31K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$692.11K derived: sum of 2 quarters · filed 2026-08-13 | -$758.98K 10-Q · filed 2025-11-13 | -$2.40M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$1.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$1.38M 10-Q · filed 2026-08-13 | -$3.02M derived: sum of 3 quarters · filed 2026-08-13 | -$487.29K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$66.87K 10-Q · filed 2026-05-14 | -$1.71M derived: sum of 2 quarters · filed 2026-05-14 | $827.12K derived: sum of 3 quarters · filed 2026-05-14 | $1.06M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $893.99K derived: sum of 2 quarters · filed 2026-03-30 | $1.13M derived: sum of 3 quarters · filed 2026-03-30 | $416.52K 10-K · filed 2026-03-30 |
| 2024-09-30 | $2.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.77M derived: sum of 2 quarters · filed 2025-11-13 | $2.05M 10-Q · filed 2025-11-13 | $746.81K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $233.11K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$477.47K 10-Q · filed 2025-08-13 | -$1.79M derived: sum of 3 quarters · filed 2025-08-13 | -$1.43M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$710.58K 10-Q · filed 2025-05-14 | -$2.02M derived: sum of 2 quarters · filed 2025-05-14 | -$1.66M derived: sum of 3 quarters · filed 2025-05-14 | -$144.28K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$951.63K derived: sum of 2 quarters · filed 2025-03-27 | $566.30K derived: sum of 3 quarters · filed 2025-03-27 | -$5.89M 10-K · filed 2025-03-27 |
| 2023-09-30 | $356.40K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.87M derived: sum of 2 quarters · filed 2024-11-14 | -$4.58M 10-Q · filed 2024-11-14 | $1.30M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $1.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$4.94M 10-Q · filed 2024-08-13 | $947.82K derived: sum of 3 quarters · filed 2024-08-13 | $1.07M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$6.46M 10-Q · filed 2024-05-15 | -$570.11K derived: sum of 2 quarters · filed 2024-05-15 | -$444.53K derived: sum of 3 quarters · filed 2024-05-15 | -$103.08K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $5.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $6.01M derived: sum of 2 quarters · filed 2024-03-28 | $6.35M derived: sum of 3 quarters · filed 2024-03-28 | $6.13M 10-K · filed 2024-03-28 |
| 2022-09-30 | $125.58K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $467.04K derived: sum of 2 quarters · filed 2023-11-14 | $240.80K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $341.45K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $115.22K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | -$226.24K 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $452.38K 10-K · filed 2023-03-28 | |||
| 2020-12-31 | $637.68K 10-K · filed 2022-03-31 | |||
| 2019-12-31 | $83.75K 10-K · filed 2021-03-18 | |||
| 2018-12-31 | $321.28K 10-K · filed 2020-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |